Our Shielded-Cell and Immunotherapy Pairs represent a fundamentally new approach to cellular therapy. We believe our technology platform has the potential to significantly improve HSC transplant, and will one day allow it to be given as an outpatient procedure in some circumstances.
- Cimeio Therapeutics Presents Additional Proof-of-Concept Data for SCIP Platform
- Cimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASH
- Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform
- Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline
- Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A
No comments to show.